What does Genelux Corporation do?
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia…
What is Genelux Corporation's P/E and P/B ratio?
Genelux Corporation has a P/E ratio of -2.3 and a P/B ratio of 5.56.
What is Genelux Corporation's debt-to-equity ratio?
Genelux Corporation has a debt-to-equity ratio of 0.15.
How much does Genelux Corporation owe compared with what it owns?
Genelux Corporation owes $0.39 for every $1 it owns (balance sheet Jun 2026), which is low.
What is Genelux Corporation's Positivity rank?
Genelux Corporation is ranked #3,596 of 6,774 companies globally and #1,581 of 4,000 in United States on PositoAI, with a Positivity Score of 20,422.
Does Genelux Corporation have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for Genelux Corporation.
Where can I read the latest news about Genelux Corporation?
Recent headlines about Genelux Corporation from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does Genelux Corporation have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of Genelux Corporation's current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.